Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Lung Cancer Study Locator Service 1-884-432-3892
az-lcsl@careboxhealth.com


AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Back

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Recruiting

Open to: ALL

Age: 18.0 - 130.0

Manchester Leicester London Wolverhampton Bristol Liverpool Newport Reading

Medical Conditions

Carcinoma, Non-Small-Cell Lung

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2022 Jun 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : 300 mg savolitinib (3 Ă— 100 mg tablets twice daily) Administrative route : oral

Intervention Arm Group : Savolitinib + Osimertinib;

Intervention Type : DRUG
Intervention Description : 80 mg osimertinib

(1 Ă— 80 mg tablet once daily) Administrative route : oral

Intervention Arm Group : Savolitinib + Osimertinib;

Intervention Type : DRUG
Intervention Description : Pemetrexed (500 mg/m2) Administrative route : IV infusion

Intervention Arm Group : Chemotherapy;

Intervention Type : DRUG
Intervention Description : Cisplatin (75 mg/m2) or Administrative route : IV infusion

Intervention Arm Group : Chemotherapy;

Intervention Type : DRUG
Intervention Description : Carboplatin (AUC5) Administrative route : IV infusion

Intervention Arm Group : Chemotherapy;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Manchester
    M20 4BX
  • Research Site
    Leicester
    LE1 5WW
  • Research Site
    London
    SE1 9RT
  • Research Site
    Wolverhampton
    WV10 0QP
  • Research Site
    Bristol
    BS2 8HW
  • Research Site
    Liverpool
    L7 3EW
  • Research Site
    Newport
    NP10 8FZ
  • Research Site
    Reading
    RG2 9LH

AstraZeneca Lung Cancer Study Locator Service 1-884-432-3892
az-lcsl@careboxhealth.com


AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com



The study is sponsored by AstraZeneca



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05261399
Last updated 09 January 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top